계명대학교 의학도서관 Repository

Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia

Metadata Downloads
Author(s)
Xuan JinMoo Hyun KimKi Hoon HanSoon Jun HongJeong‐Cheon AhnJung‐Hoon SungJin‐Man ChoHan Cheol LeeSo‐Yeon ChoiKyounghoon LeeWoo‐Shik KimMoo‐Yong RheeJu Han KimSeung Pyo HongByung Su YooEun Joo ChoJae‐Hwan LeePum‐Joon KimChang‐Gyu ParkMin Su HyonJin Ho ShinSang Hyun LeeKi Chul SungJinyong HwangKihwan KwonIn‐Ho ChaeJeong‐Sook SeoHyungseop KimHana LeeYoonhwa ChoHyo‐Soo Kim
Keimyung Author(s)
Kim, Hyung Seop
Department
Dept. of Internal Medicine (내과학)
Journal Title
Journal of clinical hypertension (Greenwich, Conn.)
Issued Date
2020
Volume
22
Issue
10
Keyword
amlodipinedyslipidemiahypertensionrosuvastatintelmisartan
Abstract
Single risk factors, such as hypertension and dyslipidemia, can combine to exacerbate the development and severity of cardiovascular disease. Treatment goals may be more effectively achieved if multiple disease factors are targeted with combination treatment. We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg, telmisartan 80 mg + rosuvastatin 20 mg, and telmisartan/amlodipine 80/5 mg. The primary efficacy variables were changes from baseline in mean sitting systolic blood pressure (MSSBP) between telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan 80 mg + rosuvastatin 20 mg at 8 weeks, and the percent changes from baseline in low-density lipoprotein (LDL) cholesterol between telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan/amlodipine 80/5 mg at 8 weeks. The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow-up. There were no significant differences between the three groups in demographic characteristics and no significant difference among the three groups in terms of baseline characteristics for the validity evaluation variables. The mean overall treatment compliance in the three groups was, respectively, 98.42%, 96.68%, and 98.12%, indicating strong compliance for all patients. The Least-Square (LS) mean (SE) for changes in MSSBP in the two (telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan 80 mg + rosuvastatin 20 mg) groups were -19.3 (2.68) mm Hg and -6.69 (2.76) mm Hg. The difference between the two groups was significant (-12.60 (2.77) mm Hg, 95% CI -18.06 to -7.14, P < .0001). The LS Mean for the percent changes from baseline in LDL cholesterol in the two (telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg and telmisartan/amlodipine 80/5 mg) groups were -52.45 (3.23) % and 2.68 (3.15) %. The difference between the two groups was significant (-55.13 (3.20) %, 95% CI -61.45 to -48.81, P < .0001). There were no adverse events leading to discontinuation or death. Combined administration of telmisartan/amlodipine 80/5 mg and rosuvastatin 20 mg for the treatment of hypertensive patients with dyslipidemia significantly reduces blood pressure and improves lipid control. ClinicalTrials.gov identifier: NCT03067688.
Keimyung Author(s)(Kor)
김형섭
Publisher
School of Medicine (의과대학)
Citation
Xuan Jin et al. (2020). Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. Journal of clinical hypertension (Greenwich, Conn.), 22(10), 1835–1845. doi: 10.1111/jch.13893
Type
Article
ISSN
1751-7176
Source
https://onlinelibrary.wiley.com/doi/10.1111/jch.13893
DOI
10.1111/jch.13893
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43143
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.